This website is for UK Healthcare Professionals only

This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below

Some patients may not be suitable for PRODUODOPA. You are strongly advised to read the Prescribing information (PI), and Summary of Product Characteristics (SmPC) for Great Britain (GB) or Northern Ireland (NI) which can be found via the links above, to evaluate patient suitability for PRODUODOPA.

Now they can have more ‘ON’ time without troublesome dyskinesia compared to oral immediate-release (IR) levodopa/carbidopa at 12 weeks3

The first subcutaneous continuous levodopa-based therapy for patients with advanced Parkinson’s disease1,2

PRODUODOPA (foslevodopa/foscarbidopa) 240 mg/12 mg per ml solution for infusion is a prodrug combination of levodopa monophosphate and carbidopa monophosphate (ratio 20:1) in a solution for 24 hour/day continuous subcutaneous infusion in advanced Parkinson’s disease patients who are not adequately controlled with current medical therapy.1,2

Foslevodopa and foscarbidopa are converted in‑vivo to levodopa and carbidopa.1,2

Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.

NICE RECOMMENDATION

Foslevodopa–foscarbidopa is recommended as an option for treating advanced levodopa-responsive Parkinson’s in adults whose symptoms include severe motor fluctuations and hyperkinesia or dyskinesia, when available medicines are not working well enough, only if:4

  • They cannot have apomorphine or deep brain stimulation, or these treatments no longer control symptoms, and
  • The company provides foslevodopa–foscarbidopa according to the commercial arrangement

Link will take you to a third party website, not controlled by Abbvie.

SMC RECOMMENDATION

Following an abbreviated submission: foslevodopa-foscarbidopa (Produodopa®) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.

SMC restriction: for use in patients not eligible for deep brain stimulation (DBS).

Foslevodopa-foscarbidopa offers an additional treatment choice in the therapeutic class of dopa and dopa derivatives for this indication.

Another medicine within this therapeutic class has been accepted via the orphan medicine process for this indication.

This advice applies only in the context of an approved NHS Scotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Link will take you to a third party website, not controlled by AbbVie.

CLINICAL DATA

PRODUODOPA efficacy and safety data from the 12 and 52 week studies3,5

SAFETY

Read safety information including adverse events for PRODUODOPA

DOSING AND ADMINISTRATION

Learn about the dosing and administration of PRODUODOPA

CLINICAL DATA

PRODUODOPA efficacy and safety data from the 12 and 52 week studies3,5

SAFETY

Read safety information including adverse events for PRODUODOPA

DOSING AND ADMINISTRATION

Learn about the dosing and administration of PRODUODOPA

RESOURCES

Learn more about PRODUODOPA with these resources

Please refer to the PRODUODOPA Summary of Product Characteristics (SmPC) for further information on adverse events, contraindications and special warnings and precautions for use.

References

  1. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) GB Summary of Product Characteristics.
  2. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) NI Summary of Product Characteristics.
  3. Soileau MJ, et al. Lancet Neurol. 2022;21:1099–1109.
  4. NICE. Full guidance. Foslevodopa-foscarbidopa for treating Parkinson’s disease with motor symptoms (GID-TA10772). Available at: https://www.nice.org.uk/guidance/ta934/resources/foslevodopafoscarbidopa-for-treating-advanced-parkinsons-with-motor-symptoms-pdf-82615608069829. Accessed: July 2024.
  5. Scottish Medicines Consortium. Medicines advice. foslevodopa-foscarbidopa (Produodopa) 240mg/mL + 12mg/mL solution for infusion (Produodopa®). Available at: https://www.scottishmedicines.org.uk/medicines-advice/foslevodopa-foscarbidopa-produodopa-abb-smc2574/. Accessed: July 2024.
  6. Aldred J, et al. Neurol Ther. 2023 Aug 26. doi: 10.1007/5. s40120-023-00533-1.

References

  1. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) GB Summary of Product Characteristics.
  2. PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) NI Summary of Product Characteristics.
  3. Soileau MJ, et al. Lancet Neurol. 2022;21:1099–1109.
  4. NICE. Full guidance. Foslevodopa-foscarbidopa for treating Parkinson’s disease with motor symptoms (GID-TA10772). Available at: https://www.nice.org.uk. Accessed: July 2024.
  5. Scottish Medicines Consortium. Medicines advice. foslevodopa-foscarbidopa (Produodopa) 240mg/mL + 12mg/mL solution for infusion (Produodopa®). Available at: https://www.scottishmedicines.org.uk. Accessed: July 2024.
  6. Aldred J, et al. Neurol Ther. 2023 Aug 26. doi: 10.1007/5. s40120-023-00533-1.

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

Adverse events should also be reported to AbbVie on [email protected]

UK-PRODD-240133. Date of preparation: July 2024.